viru
tradit
viral
isol
cell
cultur
assay
convent
serolog
method
previou
sli
use
detect
identifi
variou
viru
infect
recent
howev
molecular
method
ie
hybrid
amplif
techniqu
develop
accur
rapidli
detect
viral
organ
improv
sensit
specif
also
advanc
techniqu
provid
laboratori
decreas
handson
time
shorter
time
result
howev
routin
implement
nucleic
acid
dna
rna
amplif
hybrid
methodolog
associ
limit
particularli
clinic
laboratori
se
limit
pitfal
includ
limit
increas
costtest
due
expens
instrument
reagent
amplif
carryov
contamin
standard
posit
neg
assay
control
integr
coamplifi
intern
dna
control
demonstr
absenc
polymeras
pcr
inhibitor
amplif
prevent
falseposit
falseneg
report
due
antigen
pathogen
nucleic
acid
sequenc
drift
accur
interpret
data
softwar
analys
specimen
collect
adequ
specimen
materi
import
molecular
diagnosi
virus
whole
blood
ml
collect
ethylenediamin
tetra
acet
acid
edta
lavend
top
tube
store
freez
plasma
collect
ml
whole
blood
edta
acid
citrat
dextros
acd
solut
plasma
prepar
tube
ppt
becton
dickinson
franklin
lake
nj
steril
tube
store
whole
blood
room
temperatur
hour
remov
plasma
cell
within
hour
collect
centrifug
minut
clarifi
filtrat
centrifug
store
plasm
within
minut
separ
plasma
may
also
store
nonfrostfre
freezer
n
hour
colder
freezer
avail
ship
dri
ice
overnight
deliveri
minimum
volum
specimen
ml
plasma
urin
first
ml
void
urin
collect
steril
urinalysi
contain
steril
screwcap
tube
prefer
store
hour
store
long
term
bronchial
lavagetrach
aspir
ml
collect
steril
tube
store
bone
marrow
ml
collect
edta
tube
store
freez
tissu
approxim
em
tissu
block
collect
steril
screwtop
contain
add
small
amount
salin
keep
moist
avoid
use
viral
transport
media
avoid
potenti
inhibit
pcr
fresh
tissu
store
noc
immedi
preserv
nucleic
acid
paraffinembed
tissu
accept
usual
section
thick
suffici
pcr
analysi
tissu
section
must
deparaffin
xylen
dna
extract
fecal
steril
swab
plastic
shaft
small
fecal
sampl
place
ml
steril
salin
contain
tight
fit
lid
use
viral
transport
media
avoid
potenti
inhibit
pcr
swab
steril
swab
plastic
shaft
place
ml
steril
salin
use
viral
transport
media
avoid
potenti
inhibit
pcr
cerebrospin
fluid
csf
ml
fluid
frozen
submit
steril
leakproof
tube
analyt
perform
analyt
sensit
determin
lowest
number
target
detect
assay
crossreact
specif
determin
assay
produc
falseposit
result
presenc
high
concentr
similar
unrel
pathogen
bacteria
yeast
viru
linear
evalu
log
differ
expect
concentr
differ
within
log
ratio
observ
mean
quantit
expect
concentr
within
quantit
rang
measur
concentr
within
linear
rang
good
reproduc
clinic
perform
limit
detect
lod
lowest
concentr
target
nucleic
acid
detect
detect
cutoff
replic
usual
replic
detect
cutoff
point
assay
quantit
scale
neg
specimen
produc
result
cutoff
confid
reproduc
reproduc
test
usual
establish
test
three
six
sampl
panel
known
concentr
target
triplic
quadrupl
commerci
panel
use
establish
paramet
avail
reproduc
expr
se
percent
coeffici
variat
cv
quantit
assay
cv
rang
precis
reproduc
test
result
eg
interand
intratechnologist
interand
intraassay
hiv
viru
consist
spheric
viral
particl
encas
lipid
bilay
deriv
host
cell
cover
protrud
peglik
structur
compos
glycoprotein
viru
core
nucleocapsid
contain
major
capsid
protein
two
copi
genom
rna
three
viral
enzym
proteas
revers
transcriptas
rt
integras
viral
replic
entri
host
cell
requir
bind
gp
molecul
viru
molecul
host
cell
surfac
two
surfac
molecul
chemokin
receptor
forchemokin
uchemokin
also
requir
entri
bound
viral
envelop
fuse
cell
membran
viru
rna
enzym
enter
cytoplasm
rt
allow
singlestrand
rna
viru
copi
doublestrand
dna
dsdna
gener
integras
facilit
integr
viral
dna
cellular
chromosom
cell
divid
provid
latenc
enabl
viru
effect
evad
host
respons
viral
protein
facilit
proteas
assembl
viral
particl
use
host
cell
proteinmak
machineri
hivinfect
cell
necessarili
lyse
cull
replic
fact
mani
viral
particl
bud
cell
cycl
begin
gag
pol
env
gene
encod
structur
protein
new
viru
particl
six
gene
tat
rev
nef
vif
vpr
vpu
regul
synthesi
assembl
viral
particl
phylogeni
analysi
nucleotid
sequenc
env
gene
enabl
classif
hivl
three
group
major
n
nonm
outlier
group
hivl
infect
classifi
nine
differ
genet
subtyp
ak
present
group
hivl
global
caus
human
infect
subtypeclad
b
preval
develop
world
hiv
transmit
via
sexual
contact
blood
via
transfus
blood
product
contamin
needl
passag
mother
child
utero
birth
ingest
breast
milk
lymphocyt
count
quantit
cell
first
effect
predictor
hiv
progr
sion
still
use
person
infect
hivl
variant
accur
quantit
use
viral
load
assay
cell
count
cellsrum
import
determin
stage
hiv
diseas
indic
need
prophylaxi
opportunist
pathogen
measur
trend
percentag
addit
absolut
count
must
perform
prior
initi
adjust
antiretrovir
arv
treatment
manag
decis
percentag
may
wide
vari
due
concurr
medic
condit
subset
interlaboratori
variat
name
viral
cultur
although
specif
singleposit
cultur
must
confirm
second
specimen
least
sensit
specif
screen
assay
although
sensit
detect
earli
seroconvers
disadvantag
labor
intens
prone
subject
interp
retat
costli
screen
assay
altern
antibodi
scree
ning
assay
qualit
food
drug
admin
istrat
fda
approv
assay
test
bodi
fluid
blood
patient
sampl
drug
artifici
condit
laboratori
although
phenotyp
direct
measur
resist
complex
genotyp
therefor
slower
costli
perform
consensu
genotyp
vs
phenotyp
howev
anticip
genotyp
use
often
greater
access
lower
cost
faster
turnaround
time
mechan
resist
hiv
highli
polymorph
g
viru
quasispeci
replic
convert
rna
dna
action
viral
rt
enzym
rt
enzym
littl
proof
read
correct
capac
therefor
error
incorpor
provir
dna
replic
time
error
concis
drug
bind
site
provid
select
advantag
viru
presenc
arv
drug
resist
viru
predomin
subsequ
increas
viral
load
howev
extent
resist
implic
choic
therapi
determin
read
sequenc
gene
encod
proteas
rt
enzym
twostep
procedur
first
amplifi
proteas
rt
region
hivi
genom
use
rtpcr
amplifi
dna
sequenc
yield
nucleotid
profil
viru
use
sequenc
gel
sequenc
gener
compar
wildtyp
hivi
sequenc
differ
confer
drug
resist
highlight
viroseqtm
hivi
genotyp
system
celera
diagnost
alameda
ca
distribut
abbott
laboratori
abbott
park
il
twostep
procedur
first
amplifi
proteas
rt
region
hivi
genom
use
rtpcr
cycl
sequenc
amplifi
dna
sequenc
yield
nucleotid
profil
viru
use
capillari
electrophoresi
minimum
input
viral
rna
assay
copiesml
use
ml
plasma
succ
sful
genotyp
pitfal
genotyp
genotyp
variant
compris
sampl
may
detect
genotyp
result
reflect
predomin
subtyp
interpret
genotyp
result
base
hivi
clade
b
preval
clade
develop
world
howev
subtyp
recombin
hivi
may
undetect
assess
hivi
resist
complic
replic
kinet
resist
mutant
resist
ant
mutant
often
less
fit
wildtyp
viru
may
becom
undetect
select
drug
nevertheless
mutant
persist
patient
select
drug
pressur
reappli
mutant
replic
resist
popul
quickli
predomin
plasma
hiv
rna
surrog
marker
hiv
diseas
progress
use
guid
monitor
therapi
manag
arv
therapi
implement
patient
follow
clinic
find
symptomat
hiv
infect
aidsdefin
condit
count
cellsrum
viral
load
z
copiesml
pregnant
mother
copiesml
initi
highli
activ
arv
therapi
goal
arv
therapyna
patient
abl
attain
viral
load
copiesml
includ
ration
sequenc
arv
agent
achiev
maximum
possibl
viral
replic
suppress
arv
treatmentna
patient
patient
success
treatment
regimen
monitor
viral
load
measur
baselin
everi
week
initi
everi
month
maxim
suppress
attain
although
patient
count
cellsmm
may
requir
less
frequent
viral
load
monitor
typic
patient
begin
therapi
chang
therapi
result
virolog
failur
viral
load
measur
week
therapi
initi
decreas
least
log
lofold
indicateseffect
therapi
patient
reach
goal
copiesml
within
month
absent
incomplet
respons
viral
load
arv
therapi
rais
concern
poor
patient
adher
therapi
andor
viral
resist
signific
increas
threefold
increas
viral
load
without
clear
explan
viral
load
repeat
confirm
virolog
failur
genotypicresistancetest
perform
prior
initi
treatment
arv
therapyna
patient
patient
copiesml
nonrespons
toarv
genotypicresist
test
recommend
patient
copiesml
less
discontinuedarv
therapi
year
hcv
major
caus
nona
nonb
hepat
affect
world
popul
common
rout
transmiss
via
blood
blood
product
ie
immunoglobulin
surgeri
intraven
drug
abus
significantli
reduc
advent
routin
blood
screen
sexual
transmiss
well
vertic
transmiss
mother
infant
rate
hcv
positivesens
singlestrand
rna
viru
representsth
third
genu
famili
flavivirida
genom
encod
singl
open
read
frame
code
structur
one
core
two
envelop
protein
well
seri
nonstructur
protein
figur
untransl
region
ntr
constant
use
hcv
rna
assay
genotyp
core
region
constant
use
genotyp
assay
core
protein
assay
pcr
restrict
fragment
length
polymorph
rflpd
recombin
immunoblot
assay
riba
test
envelop
region
hypervari
region
associ
high
rate
mutat
quasispeci
code
proteas
region
code
proteasehelicas
riba
test
target
region
region
cloop
antigen
use
antihcv
riba
test
target
region
region
code
interferon
respons
element
region
code
rna
polymeras
antigen
use
antihcv
riba
test
target
region
hcv
consist
heterogen
group
genotyp
basedon
sequenc
homolog
ntr
current
six
type
subtyp
type
distribut
worldwid
type
la
lb
respons
approxim
infect
type
occursprimarili
middl
east
type
southafrica
type
hong
kong
unit
state
approxim
peopleinfect
hepat
c
havegenotyp
othersar
type
genotyp
commonin
unit
state
littlediffer
mode
transmiss
natur
histori
infect
among
differentgenotyp
cure
rate
antivir
therapi
notablyhigh
genotyp
durat
hcv
therapyi
shorter
genotyp
prior
isol
viru
hepat
infect
hepat
c
previous
known
nona
nonb
hepat
unit
state
approxim
million
expos
viru
million
chronic
carrier
acut
infect
usual
asymptomat
patient
develop
acut
hepat
jaundic
abnorm
liver
function
blood
plasma
serum
collect
sampl
edta
plasma
rapid
separ
serum
plasma
cell
recommend
centrifug
within
hour
collect
unsepar
edta
plasma
stabl
room
temperatur
hour
collect
separ
serum
plasma
stabl
room
temperatur
day
refriger
temperatur
week
frozen
year
serolog
studi
enzym
immunoassay
eia
detect
hcv
antibodi
recommend
initi
test
identif
hcv
use
screen
risk
popul
eia
compar
inexpens
reproduc
carri
high
sensit
specif
eia
detect
antibodi
week
infect
neg
eia
usual
suffici
exclud
diagnosi
hcv
infect
immunocompet
patient
howev
test
fals
neg
immunodefici
end
stage
renal
diseas
patient
seroconvert
usual
remain
posit
hcv
antibodi
thu
presen
hcv
antibodi
may
reflect
remot
recent
infect
new
total
hcv
core
antigen
elisa
ortho
diagnost
detect
quantif
total
core
antigen
blood
donor
test
posit
antihcv
antibodi
prospect
lowrisk
popul
screen
total
hcv
core
antigen
elisa
quantit
ortho
clinic
diagnost
sensit
close
pcr
assay
diagnos
acut
hcv
infctio
window
period
hcv
antibodi
develop
also
use
monitor
respons
antivir
treatment
riba
hybrid
wash
streptavidinlabel
alkalin
phosphatas
ad
follow
incub
chromogen
result
develop
purplebrown
precipit
match
probe
biotinyl
pcr
product
hybrid
amplicon
one
line
strip
allow
classif
six
major
genotyp
common
subtyp
invad
assay
third
wave
technolog
madison
wi
appli
new
dnascan
method
term
cleavas
fragment
length
polymorph
reli
format
uniqu
secondari
structur
result
dna
allow
cool
follow
brief
heat
denatur
serv
substrat
structurespecif
cleavas
enzym
gener
set
cleavag
product
format
secondari
structur
sensit
nucleotid
sequenc
presenc
sequenc
polymorph
result
gener
uniqu
collect
cleavag
product
structur
fingerprint
target
wellconserv
noncod
region
ofhcv
import
note
genotyp
bia
possibl
hcv
molecular
assay
extens
genet
heterogen
viru
falseposit
result
due
contamin
detect
neg
control
falseneg
result
due
amplif
inhibit
detect
intern
control
due
loss
viral
dna
specimen
prepar
homebrew
laboratori
develop
pcr
assay
standard
variat
sampl
handl
laboratori
method
affect
sensit
assay
hcv
test
use
highrisk
patient
intraven
drug
user
children
born
hcv
posit
mother
hiv
posit
patient
figur
show
algorithm
hcv
test
patient
suspici
chronic
hcv
infect
test
hcv
antibodi
hcv
rna
test
perform
patient
posit
antihcv
test
patient
consid
antivir
treatment
requir
quantit
monitor
patient
unexplain
liver
diseas
neg
antihcv
result
immunocompromis
suspici
acut
hcv
infect
hcv
genotyp
determin
hcv
infect
individu
prior
treatment
guid
durat
therapi
likelihood
respons
treatment
choic
peginterferon
plu
ribavirin
hbv
infect
hbv
envelop
dsdna
hepadnaviru
spheric
viru
three
import
polypeptid
hepat
b
surfac
antigen
hbsag
envelop
protein
hepat
b
core
antigen
hbcag
core
protein
hepat
b
e
antigen
hbeag
earli
protein
nonstructur
protein
code
core
gene
envelop
protein
involv
viral
bind
releas
suscept
cell
inner
capsid
reloc
dna
genom
cell
nucleu
viral
mrna
transcrib
hbv
circular
partial
dsdna
viru
approxim
nucleotid
highli
compact
genom
contain
four
open
read
frame
encod
envelop
presi
core
core
precor
polymeras
x
protein
figur
although
hepatocyt
suscept
infect
cell
type
may
affect
lesser
extent
life
cycl
hbv
begin
attach
cell
surfac
cytoplasm
dna
still
core
capsid
remov
dna
pass
nucleu
form
coval
close
circular
dna
cccdna
hbv
use
host
transcript
machineri
replic
gene
use
rna
polymeras
ii
host
strand
cccdna
act
templat
transcript
transcript
mrna
translat
host
protein
synthesi
machineri
form
viral
protein
endoplasm
reticulum
protein
assembl
virion
secret
hbv
recogn
endem
china
part
asia
onethird
world
popul
activ
infect
hbv
hbv
strain
classifi
seven
genom
group
genotyp
design
ag
base
nucleotid
homolog
surfac
gene
predomin
hbv
genotyp
cluster
geograph
region
genotyp
mainli
found
northwestern
europ
north
america
africa
wherea
genotyp
band
c
describ
southeastern
asian
popul
genotyp
e
f
seen
east
africa
respect
genotyp
often
found
southern
europ
part
central
asia
india
africa
middl
east
genotyp
g
recent
determin
genotyp
franc
america
germani
genotyp
h
report
patient
central
america
clinic
present
figur
transmit
parenter
sexual
contamin
open
cut
mucou
membran
long
incub
period
day
major
affect
patient
recov
ill
character
anorexia
nausea
vomit
headach
fever
abdomin
pain
dark
urin
sometim
jaundic
elev
transaminas
hyperbilirubinemia
elev
alkalin
phosphatas
may
also
occur
extrahepat
manifest
includ
arthralagia
arthriti
nephriti
dermat
patient
continu
carri
viru
marker
activ
viral
infect
month
initi
infect
small
percentag
may
develop
chronicpersist
hepat
sequenc
fibrosi
cirrhosi
incid
hepatocellular
carcinoma
increas
viral
genom
found
integr
cellular
dna
case
may
associ
polyarter
cryoglobulinemia
viral
load
test
use
assess
monitor
therapi
respons
hibv
infect
figur
hbv
carrier
activ
liver
diseas
hbv
dna
load
measur
assess
patient
regard
need
either
interferona
lamivudin
dna
polymeras
inhibitor
antivir
therapi
also
monitor
effect
increas
hbv
viral
load
also
use
marker
emerg
lamivudineresist
viral
mutant
ic
defin
concentr
antivir
agent
result
reduct
viral
nucleic
acid
hybrid
valu
ie
dna
synthesi
compar
hybrid
valu
control
disadvantag
dna
hybrid
assay
requir
use
radiolabel
probe
dna
hybrid
assay
advantag
plaqu
reduct
assay
elimin
variat
due
subject
error
result
plaqu
count
differ
individu
phenotyp
method
viral
product
measur
use
ifa
immunoperoxidas
elisa
flow
cytometrybas
method
detect
quantit
cell
express
cmv
antigen
immediateearli
earli
late
genotyp
method
mutat
viral
phosphotransferas
gene
code
sequenc
may
confer
resist
ganciclovir
mutat
occur
three
specif
site
within
region
end
gene
includ
point
mutat
within
codon
either
point
mutat
delet
within
codon
rang
specif
primer
specif
design
ebv
viral
latent
membran
protein
intern
competitor
dna
ssdna
confirm
known
number
namalwa
cell
cell
line
contain
two
integr
copi
ebv
viral
genom
per
cell
four
separ
pcr
reaction
tube
contain
intern
competitor
dna
copiesul
copiesul
copiesul
copiesul
place
competit
ebvspecif
primer
amplif
patient
dna
pcr
ampli
con
examin
electrophoresi
agaro
se
gel
visual
use
gelimag
document
system
band
densiti
quantit
measur
use
biorad
hercul
ca
quantiti
one
softwar
use
calcul
ebv
copi
detect
lmp
gene
ebv
viral
genom
ebv
amplifi
specif
primer
pcr
reaction
amplicon
detect
fluoresc
use
specif
pair
hybrid
probe
melt
curv
analysi
perform
pcr
run
differenti
posit
sampl
nonebv
speci
ie
herp
viru
famili
intern
control
ad
alreadi
lyse
sampl
purif
step
copurifiedamplifi
ebv
dna
specimen
pcr
reaction
dual
color
detect
lod
realtim
lc
pcr
copiesml
linear
rang
copiesml
elvi
method
specif
manufactur
techniqu
combin
cell
cultur
amplif
hsvactiv
report
gene
test
produc
result
equal
convent
cultur
homebrew
method
design
primer
thymidin
kinas
gene
due
lack
standard
variat
sensit
specif
observ
detect
differenti
hsv
type
type
hsv
hsv
amplifi
specif
primer
pcr
reaction
amplicon
detect
fluoresc
use
specif
pair
hybrid
probe
melt
curv
analysi
perform
pcr
run
differenti
posit
sampl
hsv
hsv
melt
point
hsv
hsv
significantli
differ
hsvi
wherea
allow
clear
determin
hsv
type
figur
intern
control
ad
alreadi
lyse
sampl
purif
step
copurifiedlamplifi
hsv
dna
specimen
pcr
reaction
dual
color
detect
target
region
hsv
type
type
polymeras
gene
target
glycoprotein
gene
hsv
type
glycoprotein
g
gene
hsv
type
lower
lod
analyt
sensit
hsv
qualit
pcr
copiesreact
copiesml
sensit
pcr
hsv
skin
lesion
sensit
specif
csf
sensit
hsv
detect
frequent
pcr
viral
cultur
regardless
whether
sampl
obtain
hsv
lesion
genit
oral
secret
period
subclin
shed
yield
viru
posit
four
time
greater
pcr
cultur
result
reliabl
especi
set
transport
climat
may
interfer
yield
viral
cultur
target
vzv
orf
gene
lad
copiesml
vzv
genom
analyt
sensit
copyul
recogn
necessari
factor
develop
cervic
cancer
genom
hpv
viru
circular
figur
genom
eight
open
read
frame
encod
ten
protein
gene
divid
earli
region
express
skin
infect
basal
cell
yet
differenti
late
region
two
gene
whose
protein
product
exist
cell
cell
differenti
chang
cellular
respons
program
cell
death
apoptosi
bind
tumor
supressor
protein
bind
inactiv
retinoblastoma
protein
rb
protein
earli
viral
protein
express
upon
infect
caus
destabil
infect
cell
induc
replic
cell
differenti
migrat
upward
induc
express
gene
ej
caus
viral
replic
destabil
cytoskeleton
prevent
cellular
differenti
upper
epitheli
cell
layer
late
viral
protein
major
capsid
protein
minor
capsid
protein
express
bind
viral
dna
autoassembl
give
rise
complet
virion
readi
new
infect
releas
keratinocyt
desquam
common
mode
transmiss
via
contact
ie
sexual
autoinocul
hpv
far
common
sexual
transmit
diseas
estim
sexual
activ
adult
infect
one
genit
hpv
strain
vast
major
infect
adult
experi
transient
infect
unawar
condit
howev
may
abl
infect
other
howev
women
infect
highrisk
hpv
especi
women
year
age
develop
cervic
cancer
immun
system
effect
clear
infect
cours
sever
month
specif
factor
determin
hpv
infect
persist
develop
squamou
intraepitheli
lesion
current
unknown
cigarett
smoke
ultraviolet
radiat
pregnanc
folat
defici
immun
suppress
implic
possibl
cofactor
lowrisk
hpv
type
hpv
produc
benign
epitheli
tumor
skin
mucou
membran
infect
certain
type
hpv
high
risk
also
increas
risk
develop
cervic
cancer
type
condit
associ
hpv
verucca
vulgari
common
wart
associ
highli
contagi
spread
site
skin
mucou
membran
via
autoinocul
condyloma
acuminatum
vener
wart
associ
hpvll
consid
sexual
transmit
diseas
lesion
occur
site
sexual
contact
trauma
ie
mucou
membran
genitalia
perian
region
oral
caviti
larynx
flat
wartsmost
commonli
found
face
forehead
common
children
teen
plantar
wartsar
found
sole
feet
subungu
periung
wartswart
form
fingernail
subungu
around
fingernail
cuticl
periungu
subtyp
common
skin
wart
may
difficult
cure
wart
locat
butcher
wart
caus
occur
peopl
handl
meat
poultri
fish
focal
epitheli
hyperplasia
heck
diseas
caus
possibl
commonli
occur
nativ
american
inuit
childhood
condit
character
multipl
soft
nontend
flat
papul
plaqu
oral
mucou
membran
laryng
papillomatosisfrequ
recur
may
requir
repetit
surgeri
interfer
breath
rare
case
progress
laryng
cancer
hivassoci
immunocompromis
state
cervic
cancerhistori
hpv
highrisk
type
infect
strongli
associ
develop
cervic
cancer
howev
hpv
infect
progress
cervic
cancer
progress
transform
normal
cervic
cancer
cell
slow
process
cancer
occur
peopl
infect
hpv
long
time
usual
decad
use
tissu
section
liquidbas
cytolog
specimen
cervic
smear
slide
detect
highand
lowrisk
hpv
genotyp
probe
cocktail
highrisk
hpv
genotyp
six
probe
cocktail
lowrisk
hpv
genotyp
ii
digen
hybrid
captur
ii
digen
corpor
gaithersburg
md
method
util
rna
probe
mix
detect
l
gene
hpi
assay
identifi
hr
hpv
type
addit
kit
detect
lowrisk
viru
ii
also
avail
signal
amplif
base
immunocaptur
dnajrna
hybrid
immobil
micropl
react
alkalin
phosphataseconjug
antibodi
specif
rna
dna
hybrid
detect
chemiluminesc
substrat
detect
viral
copi
per
sampl
pg
hpv
dna
per
sampl
invad
assay
third
wave
technolog
method
use
isotherm
signal
amplif
detect
hr
hpv
type
util
three
probe
pool
base
phylogeni
related
three
probe
pool
includ
pool
invad
isotherm
linear
signal
amplif
use
structurespecif
oligonucleotid
cleavag
appli
dnabas
genotyp
use
pool
biotinyl
primer
defin
sequenc
nucleotid
region
hpv
genom
design
amplifi
hpv
dna
hpv
genotyp
includ
highrisk
genotyp
bglobulin
gene
concurr
isol
ensur
adequaci
cellular
extract
amplif
process
sampl
overal
sensit
cytolog
detect
high
grade
squamou
intraepithelialles
hgsil
rang
specif
overal
sensit
hpv
dna
test
detect
hgsil
specif
howev
sensit
specif
influenc
age
preval
target
conserv
region
matrix
na
gene
influenza
b
sensit
specif
tabl
sensit
dfa
methodolog
depend
upon
adequaci
specimen
ie
cell
otherwis
due
length
time
requir
perform
viral
cultur
assay
poor
efficaci
result
obtain
much
patient
left
offic
well
past
time
drug
therapi
could
effect
develop
pcrbase
assay
must
alway
consid
antigen
drift
random
mutat
due
viral
evolut
may
result
falseneg
cost
avail
sensit
issu
diagnosi
influenza
often
base
clinic
criteria
present
rtpcr
taqman
assay
provid
rapid
specif
diagnosi
influenza
allow
earli
therapeut
intervent
prophylact
treatment
highrisk
patient
ie
geriatr
care
facil
molecular
diagnosi
playa
larg
role
epidemiolog
surveil
vaccin
strain
select
surveil
emerg
novel
influenza
virus
ie
hong
kong
outbreak
sequenc
analysi
influenza
virus
infect
bird
call
avian
influenza
virus
influenza
virus
subtyp
infect
bird
substanti
genet
differ
subtyp
typic
infect
peopl
bird
eragen
platform
increas
size
genet
alphabet
two
dna
base
pair
six
pair
develop
eight
new
synthet
base
new
multiplex
realtim
pcr
platform
standard
pcr
primer
need
design
sinc
report
place
directli
onto
primer
probe
target
nucleocapsid
nuc
polymeras
pol
gene
sensit
commerci
assay
rang
specif
rang
absolut
sensit
rtpcr
assay
rang
genom
equival
per
reaction
present
sar
antibodi
detect
serum
point
cours
diseas
howev
patient
seroconvert
second
week
highlight
import
rtpcr
assay
earli
diagnosi
viru
posit
result
must
confirm
repeat
test
use
aliquot
origin
specimen
andor
anoth
laboratori
report
altern
test
second
gene
region
may
help
furthermor
test
one
sampl
singl
sourc
rule
presenc
sarsassoci
coronaviru
figur
realtim
rtpcrabi
prism
appli
biosystem
foster
citi
ca
improv
speed
accuraci
use
taqman
assay
platform
target
conserv
sequenc
ntr
vp
capsid
protein
ntr
highli
conserv
region
involv
viral
protein
translat
enteroviru
realtim
taqman
pcr
analysi
serum
plasma
may
good
altern
enteroviru
cultur
fece
particularli
neonat
sepsi
target
conserv
sequenc
untransl
region
ntr
detect
region
utr
nucleic
acid
sequencebas
assay
nasbaecl
nasbabeacon
similar
sensit
bk
bkv
ic
virus
lcv
small
nonenvelop
close
circular
dsdna
viru
belong
human
polyomavirus
member
papovavirida
famili
first
isolatedin
name
ic
bk
initi
patient
first
discov
icv
isol
brain
tissu
patient
progress
multifoc
leukoencephalopathi
pml
bkv
isol
urin
renal
transplant
patient
develop
ureter
stenosi
postop
bkv
icv
share
homolog
level
nucleot
ide
sequenc
homolog
two
crossreact
serolog
serolog
test
antibodi
abl
distingui
sh
bkv
icv
adult
popul
antibodi
bkv
icv
primari
infect
typic
occur
childhood
initi
infect
polyomavirus
establish
latenc
variou
tissu
primari
site
latenc
uroepitheli
cell
bkv
biymphocyt
renal
tissu
icv
addit
site
latenc
virus
includ
uret
brain
spleen
clinic
present
